- Home
- HCKT vs COGT Comparison
HCKT vs COGT Comparison
Compare HCKT & COGT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HCKT
- COGT
- Stock Information
- Founded
- HCKT 1991
- COGT 2014
- Country
- HCKT United States
- COGT United States
- Employees
- HCKT N/A
- COGT N/A
- Industry
- HCKT Professional Services
- COGT Biotechnology: Pharmaceutical Preparations
- Sector
- HCKT Consumer Discretionary
- COGT Health Care
- Exchange
- HCKT Nasdaq
- COGT Nasdaq
- Market Cap
- HCKT 843.0M
- COGT 900.3M
- IPO Year
- HCKT 1998
- COGT 2018
- Fundamental
- Price
- HCKT $32.12
- COGT $7.91
- Analyst Decision
- HCKT Strong Buy
- COGT Buy
- Analyst Count
- HCKT 3
- COGT 6
- Target Price
- HCKT $30.00
- COGT $14.20
- AVG Volume (30 Days)
- HCKT 84.8K
- COGT 1.7M
- Earning Date
- HCKT 11-04-2024
- COGT 11-12-2024
- Dividend Yield
- HCKT 1.02%
- COGT N/A
- EPS Growth
- HCKT N/A
- COGT N/A
- EPS
- HCKT 1.22
- COGT N/A
- Revenue
- HCKT $300,739,000.00
- COGT N/A
- Revenue This Year
- HCKT $8.66
- COGT N/A
- Revenue Next Year
- HCKT $5.16
- COGT N/A
- P/E Ratio
- HCKT $26.31
- COGT N/A
- Revenue Growth
- HCKT 4.09
- COGT N/A
- 52 Week Low
- HCKT $20.23
- COGT $4.28
- 52 Week High
- HCKT $32.83
- COGT $12.61
- Technical
- Relative Strength Index (RSI)
- HCKT 68.09
- COGT 32.81
- Support Level
- HCKT $31.58
- COGT $7.94
- Resistance Level
- HCKT $32.39
- COGT $8.56
- Average True Range (ATR)
- HCKT 0.54
- COGT 0.60
- MACD
- HCKT -0.16
- COGT -0.06
- Stochastic Oscillator
- HCKT 59.28
- COGT 9.60
About HCKT Hackett Group Inc (The).
The Hackett Group Inc is an IP-based executive advisory, strategic consulting, and digital transformation firm. It provides Generative Artificial Intelligence ("Gen AI") strategy, operations, finance, human capital management, strategic sourcing, procurement, and information technology. It operates in three segments Oracle Solutions, SAP Solutions, and Global S&BT. It generates the majority of its revenue from the Global S&BT segment in the United States.
About COGT Cogent Biosciences Inc.
Cogent Biosciences Inc a biotechnology company focused on developing precision therapies for genetically defined diseases. It designs rational precision therapies that treat the underlying cause of disease and improve the lives of patients. Its program CGT9486, is a selective tyrosine kinase inhibitor designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. In the vast majority of cases, KIT D816V is responsible for driving Systemic Mastocytosis (SM), a serious disease caused by the unchecked proliferation of mast cells. Exon 17 mutations are also found in patients with advanced gastrointestinal stromal tumors (GIST), a type of cancer with strong dependence on oncogenic KIT signaling.